These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26651453)

  • 21. Rapid foot and calf compression increases walking distance in patients with intermittent claudication: results of a randomized study.
    Ramaswami G; D'Ayala M; Hollier LH; Deutsch R; McElhinney AJ
    J Vasc Surg; 2005 May; 41(5):794-801. PubMed ID: 15886663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
    Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
    Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular Reactivity is Impaired and Associated With Walking Ability in Patients With Intermittent Claudication.
    Silva Rde C; Wolosker N; Yugar-Toledo JC; Consolim-Colombo FM
    Angiology; 2015 Aug; 66(7):680-6. PubMed ID: 25100750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.
    Brendle DC; Joseph LJ; Corretti MC; Gardner AW; Katzel LI
    Am J Cardiol; 2001 Feb; 87(3):324-9. PubMed ID: 11165969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of propionylcarnitine on changes in endothelial function and plasma levels of adhesion molecules induced by acute exercise in patients with intermittent claudication.
    Silvestro A; Schiano V; Bucur R; Brevetti G; Scopacasa F; Chiariello M
    Angiology; 2006; 57(2):145-54. PubMed ID: 16518521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic endothelin antagonism restores cerebrovascular function in diabetes.
    Dumont AS; Dumont RJ; McNeill JH; Kassell NF; Sutherland GR; Verma S
    Neurosurgery; 2003 Mar; 52(3):653-60; discussion 659-60. PubMed ID: 12590691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Walking disability in patients with peripheral artery disease is associated with arterial endothelial function.
    Grenon SM; Chong K; Alley H; Nosova E; Gasper W; Hiramoto J; Boscardin WJ; Owens CD
    J Vasc Surg; 2014 Apr; 59(4):1025-34. PubMed ID: 24423479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of osteopathic manipulative treatment as adjuvant therapy in patients with peripheral arterial disease.
    Lombardini R; Marchesi S; Collebrusco L; Vaudo G; Pasqualini L; Ciuffetti G; Brozzetti M; Lupattelli G; Mannarino E
    Man Ther; 2009 Aug; 14(4):439-43. PubMed ID: 18824395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of relationship between gait parameters and physical function in peripheral arterial disease.
    Scherer SA; Hiatt WR; Regensteiner JG
    J Vasc Surg; 2006 Oct; 44(4):782-8. PubMed ID: 17012002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
    Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
    Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication.
    de Haro J; Acin F; Florez A; Bleda S; Fernandez JL
    J Vasc Surg; 2010 Apr; 51(4):857-62. PubMed ID: 20347681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between kidney disease and endothelial function in peripheral artery disease.
    Chong KC; Owens CD; Park M; Alley HF; Boscardin WJ; Conte MS; Gasper WJ; Grenon SM
    J Vasc Surg; 2014 Dec; 60(6):1605-11. PubMed ID: 25441679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.
    Russell KS; Yates DP; Kramer CM; Feller A; Mahling P; Colin L; Clough T; Wang T; LaPerna L; Patel A; Lawall H; Shennak MM; Fulmer J; Nikol S; Smith WB; Müller OJ; Ratchford EV; Basson CT
    Vasc Med; 2019 Oct; 24(5):414-421. PubMed ID: 31277561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm.
    Wilson AM; Harada R; Nair N; Balasubramanian N; Cooke JP
    Circulation; 2007 Jul; 116(2):188-95. PubMed ID: 17592080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease.
    Myers SA; Johanning JM; Stergiou N; Lynch TG; Longo GM; Pipinos II
    J Vasc Surg; 2008 Mar; 47(3):550-555. PubMed ID: 18207355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.